Abstract: SA-PO0633
Real-World Efficacy of Nefecon in Patients with IgAN and an Exploratory Comparison with Telitacicept
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Author
- Fan, Qiuling, Shanghai General Hospital, Shanghai, China
Background
To evaluate the short-term real-world efficacy of Nefecon in patients with IgA nephropathy (IgAN) and to explore its comparative efficacy with telitacicept.
Methods
This single-center retrospective cohort study enrolled patients diagnosed with IgAN at Shanghai General Hospital between January 1, 2025 and January 1, 2026 who received Nefecon treatment. A contemporaneous control cohort treated with telitacicept and meeting the same inclusion and exclusion criteria was identified. Propensity score matching (PSM) at a 1:1 ratio was performed to balance baseline characteristics. Longitudinal changes in 24-hour urinary protein and eGFR between groups were analyzed using linear mixed-effects models.
Results
A total of 109 patients treated with Nefecon were included, with a mean age of 41.6 ± 12.3 years. Baseline 24-hour urinary protein excretion was 1.11 (0.75, 2.01) g/day, and baseline eGFR was 72.50 ± 30.52 mL/min. At 6 months (n=43), median 24-hour urinary protein decreased from 1.45 (0.85, 2.06) g/day to 0.78 (0.32, 1.47) g/day, representing a 31.5% relative reduction (P=0.005). At 9 months (n=26), urinary protein decreased from 1.02 (0.85, 1.63) g/day to 0.61 (0.34, 0.88) g/day, corresponding to a 56.4% relative reduction (P=0.002). No significant changes in eGFR were observed at either 6 months (70.22 ± 35.71 vs. 69.75 ± 35.91 mL/min P=0.779) or 9 months (67.36 ± 31.82 vs. 66.29 ± 35.32 mL/min, P=0.725).Urinary red blood cell counts significantly decreased at 6 months, with a median relative reduction of 49.19% (P=0.007).After PSM, 20 patients were included (10 in the telitacicept group and 10 in the Nefecon group). Baseline balance improved, although residual imbalance remained. Linear mixed-effects models demonstrated a significant time effect on 24-hour urinary protein (P<0.001), whereas neither the treatment effect nor the interaction effect reached statistical significance. No significant effects were observed for eGFR-related outcomes.
Conclusion
In this real-world single-center cohort, Nefecon significantly reduced proteinuria in patients with IgAN at both 6 and 9 months, while renal function remained stable during short-term follow-up. Exploratory comparison with telitacicept did not demonstrate significant differences in longitudinal proteinuria reduction or eGFR changes between the two therapies.